QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
NASDAQ:BGNE

BeiGene - BGNE Stock Forecast, Price & News

$144.27
-0.67 (-0.46%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$138.01
▼
$144.80
50-Day Range
$131.80
▼
$202.24
52-Week Range
$118.18
▼
$392.30
Volume
80,212 shs
Average Volume
283,314 shs
Market Capitalization
$14.95 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$299.25

BeiGene MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
107.4% Upside
$299.25 Price Target
Short Interest
Bearish
1.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$4.68 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($17.02) to ($12.08) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

755th out of 1,072 stocks

Pharmaceutical Preparations Industry

365th out of 534 stocks

See Top Rated MarketRank™ Stocks Here
BGNE stock logo

About BeiGene (NASDAQ:BGNE) Stock

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Stock News Headlines

September 30, 2022 | finance.yahoo.com
Latest Push by Chinese Firms to Avoid Delistings Falls Short - Yahoo Finance
September 25, 2022 | americanbankingnews.com
John Oyler Sells 30,520 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock
September 20, 2022 | seekingalpha.com
BeiGene Stock A Hold Despite Rapid Revenue Growth (NASDAQ:BGNE) - Seeking Alpha
September 20, 2022 | seekingalpha.com
BeiGene: Best Biotech Industry Stock Bet Say Portfolio Wealth Builders (NASDAQ:BGNE) - Seeking Alpha
September 20, 2022 | businesswire.com
NICE Recommends BeiGene's BRUKINSA® (zanubrutinib) for Patients with Waldenström's Macroglobulinemia who have had at Least One Treatment - Business Wire
September 19, 2022 | finance.yahoo.com
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
September 19, 2022 | benzinga.com
BeiGene Receives Positive CHMP Opinion For BRUKINSA For The Treatment Of Adults With Marginal Zone Lymphoma - BeiGene (NASDAQ:BGNE) - Benzinga
September 19, 2022 | businesswire.com
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma - Business Wire
September 19, 2022 | finance.yahoo.com
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
September 16, 2022 | seekingalpha.com
EMA panel recommends extending indication for BeiGene's cancer drug Brukinsa - Seeking Alpha
September 13, 2022 | streetinsider.com
Agenus Makes Senior Regulatory and Clinical Appointments - StreetInsider.com
September 12, 2022 | finance.yahoo.com
BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors
September 10, 2022 | finance.yahoo.com
Ivy Brain Tumor Center Announces Initial Results of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma at the European Society for Medical Oncology (ESMO) 2022 Congress - Yahoo Finance
September 10, 2022 | businesswire.com
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer - Business Wire
September 10, 2022 | finance.yahoo.com
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
September 7, 2022 | businesswire.com
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference - Business Wire
September 7, 2022 | finance.yahoo.com
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 7, 2022 | finance.yahoo.com
Global Chemotherapy Market to Grow at a Significant CAGR during 2022-2031; Market to Expand on the Back of Growing Cases of Cancer and the Increasing R&D Expenditure across the Globe – Kenneth Research - Yahoo Finance
September 7, 2022 | finance.yahoo.com
ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials - Yahoo Finance
September 4, 2022 | finance.yahoo.com
Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress - Yahoo Finance
September 2, 2022 | finance.yahoo.com
National Association of Specialty Pharmacy (NASP) Welcomes New Board Members at its upcoming Annual Meeting & Expo and 10th Anniversary Celebration - Yahoo Finance
August 28, 2022 | marketwatch.com
U.S.-China relations just got a whole lot better, boosting the prospects of these three stocks - MarketWatch
August 23, 2022 | finance.yahoo.com
Bladder Cancer Clinical Trial Pipeline Insights Featuring 100+ Companies | DelveInsight - Yahoo Finance
August 23, 2022 | businesswire.com
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China - Business Wire
August 23, 2022 | finance.yahoo.com
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China
See More Headlines
Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Company Calendar

Last Earnings
8/04/2022
Today
10/05/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BGNE
CUSIP
N/A
CIK
1651308
Web
www.beigene.com
Phone
861085148500
Fax
N/A
Employees
8,200
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$299.25
High Stock Price Forecast
$431.00
Low Stock Price Forecast
$177.00
Forecasted Upside/Downside
+107.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($20.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-1,413,350,000.00
Net Margins
-187.65%
Pretax Margin
-187.04%
Return on Equity
-38.58%
Return on Assets
-27.34%

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
4.54
Quick Ratio
4.35

Sales & Book Value

Annual Sales
$1.18 billion
Price / Sales
12.71
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$60.95 per share
Price / Book
2.37

Miscellaneous

Outstanding Shares
103,632,000
Free Float
95,860,000
Market Cap
$14.95 billion
Optionable
Optionable
Beta
0.72

Social Links


Key Executives

  • Mr. John V. OylerMr. John V. Oyler (Age 54)
    Co-Founder, Exec. Chairman & CEO
    Comp: $1.75M
  • Dr. Xiaobin Wu Ph.D. (Age 60)
    Pres, COO & GM of China
    Comp: $1.64M
  • Dr. Xiaodong Wang Ph.D. (Age 59)
    Co-Founder, Chairman of Scientific Advisory Board & Non-Exec. Director
    Comp: $250k
  • Ms. Julia Wang (Age 51)
    CFO & Principal Accounting Officer
    Comp: $798.14k
  • Mr. Wang Lai (Age 45)
    Global Head of R&D
    Comp: $1.13M
  • Dr. Edna Huang M.D. (Age 49)
    Consultant
    Comp: $768.08k
  • Mr. Daniel Maller
    VP of Fin. & Accounting
  • Ms. Mi Zhou
    Sr. Director of Investor Relations
  • Mr. Kevin C. Mannix
    Sr. VP of Investor Relations.
  • Ms. Diana Lee Francis
    VP and Global Head of Quality & Regulatory Compliance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BGNE Stock - Frequently Asked Questions

Should I buy or sell BeiGene stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BGNE shares.
View BGNE analyst ratings or view top-rated stocks.

What is BeiGene's stock price forecast for 2022?

6 brokers have issued twelve-month price targets for BeiGene's stock. Their BGNE share price forecasts range from $177.00 to $431.00. On average, they predict the company's stock price to reach $299.25 in the next year. This suggests a possible upside of 110.3% from the stock's current price.
View analysts price targets for BGNE or view top-rated stocks among Wall Street analysts.

How have BGNE shares performed in 2022?

BeiGene's stock was trading at $270.93 on January 1st, 2022. Since then, BGNE shares have decreased by 47.5% and is now trading at $142.29.
View the best growth stocks for 2022 here.

When is BeiGene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our BGNE earnings forecast.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) announced its earnings results on Thursday, August, 4th. The company reported ($5.56) earnings per share for the quarter, missing analysts' consensus estimates of ($4.23) by $1.33. The firm earned $341.57 million during the quarter, compared to the consensus estimate of $297.28 million. BeiGene had a negative trailing twelve-month return on equity of 38.58% and a negative net margin of 187.65%.

What is John V. Oyler's approval rating as BeiGene's CEO?

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

How do I buy shares of BeiGene?

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $142.29.

How much money does BeiGene make?

BeiGene (NASDAQ:BGNE) has a market capitalization of $14.75 billion and generates $1.18 billion in revenue each year. The company earns $-1,413,350,000.00 in net income (profit) each year or ($20.42) on an earnings per share basis.

How many employees does BeiGene have?

The company employs 8,200 workers across the globe.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The official website for the company is www.beigene.com. The company can be reached via phone at 861085148500 or via email at ir@beigene.com.

This page (NASDAQ:BGNE) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.